Core Insights - Absci collaborates with Oracle Cloud Infrastructure (OCI) and AMD to enhance its generative AI-driven drug discovery platform, aiming to accelerate biologics design cycles and reduce costs [1][2][3] Company Overview - Absci is a clinical-stage biotech company focused on advancing novel therapeutics using generative AI, with a mission to create better biologics for patients more quickly [5] - The company utilizes an Integrated Drug Creation™ platform that combines advanced AI models with a synthetic biology data engine, facilitating rapid design and validation of therapeutics [5] Technology and Infrastructure - Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows, enabling large-scale molecular-dynamics simulations and end-to-end antibody design [2][3] - The collaboration leverages OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA networking, providing low-latency networking and high throughput for model training and simulations [3][4] - The integration of AMD's next-generation Instinct™ MI355X GPUs further enhances the performance and scalability of Absci's AI Drug Creation Platform [2][4] Industry Impact - The partnership between Absci, OCI, and AMD exemplifies how AI can transform drug discovery processes, accelerating the development of novel therapeutics [4] - The collaboration aims to push the boundaries of biologics design by combining cutting-edge AI models with high-performance infrastructure [3][4]